Last edition
News about
Biologos Appoints Hetal Patel as Chief Executive Officer
Biologos, a leading ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, announced the appointment of Hetal Patel as chief executive officer.
Servier Strikes USD 2.5 Billion Deal to Buy Day One Biopharmaceuticals
French drugmaker Servier has agreed to acquire US-based Day One Biopharmaceuticals in an all-cash deal valued at approximately USD 2.5 billion, as the company seeks to strengthen its presence in rare oncology and brain tumour therapies.
UK Space Agency Launches Initiative to Accelerate Development of Space-Manufactured Medicines
UK Space Agency, with Medicines and Healthcare products Regulatory Agency and partners, unveils regulatory support and innovation programmes to help companies develop microgravity-manufactured medicines and bring them from orbit to patients.
GAIA AG and Daiichi Sankyo Europe form an exclusive partnership to commercialise lipodia, a digital therapeutic designed to help adults with Hypercholesterolemia adopt sustainable lifestyle changes for improved cardiovascular health.
U.S. Food and Drug Administration grants rapid approval to Tec-Dara, a combination of teclistamab and daratumumab hyaluronidase-fihj, for adults with relapsed or refractory multiple myeloma after at least one prior therapy.
Alembic Pharmaceuticals reports first prescription sale of Pivya in the US, marking its entry into the branded pharmaceutical segment with a first-line oral antibiotic for uncomplicated urinary tract infections in women.
US FDA Clears Sotyktu for Active Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved Sotyktu, developed by Bristol Myers Squibb, for adults with active psoriatic arthritis. The once-daily oral TYK2 inhibitor showed significantly higher ACR20 response rates versus placebo in the phase-III POETYK PsA-1 and PsA-2 trials.
Women's Leadership in UK Biotech Stagnates Despite Strong Funding Wins by Female CEOs: BIA Report
A new BioIndustry Association report finds women’s representation in UK biotech leadership largely unchanged, with female CEOs at 18.7 percent, while funding gains remain concentrated among a few standout companies.
Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy
Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.
XYRA receives a US patent protecting dose-adjusted budiodarone therapy for atrial fibrillation, aiming to reduce stroke and heart failure risk through patient monitoring while offering a safer rhythm-control option.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy